22nd Century Group Inc. - XXII STOCK NEWS

22nd Century Group, Inc. (NYSE American: XXII) supports Congresswoman Gwen Moore's call to the federal government for legislation to reduce nicotine levels in cigarettes to minimally or non-addictive levels. The company is ready to deliver its VLN® reduced nicotine content cigarette in alignment with FDA proposals. VLN® offers 95% less nicotine than traditional cigarettes. The company aims to address health disparities among minority communities, with high smoking rates especially among low-income African-Americans. 22nd Century believes it is close to obtaining a Modified Risk Tobacco Product designation from the FDA.

22nd Century Group (NYSE American: XXII) has provided over 31 million variable nicotine content research cigarettes for independent studies, supporting the FDA's proposed mandate to reduce nicotine levels in U.S. cigarettes. The company fulfilled a recent order of 3.6 million research cigarettes, demonstrating substantial public health benefits from reduced nicotine content (RNC) products, like their VLN® cigarettes, which contain 95% less nicotine. 22nd Century is poised to supply its VLN® cigarettes upon FDA authorization, aiming to enhance public health and reduce smoking addiction.

22nd Century Group, Inc. (NYSE American: XXII) will host a live audio webcast on May 6, 2021, at 10:00 AM ET to discuss its first quarter 2021 results, which will be released at 6:00 AM ET the same day. CEO James A. Mish and other executives will outline the company's performance and strategic priorities in the tobacco, hemp/cannabis, and a new plant-based franchise market worth over $1.3 trillion. The session will also include a Q&A segment for analysts and investors. Access to the webcast will be available on the company’s Investor Relations webpage.

22nd Century Group, Inc. (NYSE American: XXII) has expressed confidence in the approval of its Modified Risk Tobacco Product (MRTP) application for VLN® cigarettes, which contain 95% less nicotine. The company's letter to shareholders highlights a significant market opportunity, given the global tobacco market's worth of over $800 billion. With 60% of smokers likely to use VLN®, 22nd Century is poised to introduce this product within 90 days of FDA authorization. The firm also aims to innovate within hemp/cannabis, targeting a market projected to exceed $100 billion by 2024.

22nd Century Group (NYSE American: XXII) is poised to launch its VLN® reduced nicotine content cigarettes in collaboration with the FDA. This initiative aligns with the Biden Administration's focus on public health, potentially aiding 5 million smokers to quit and preventing new smokers. Their reduced nicotine cigarettes contain 95% less nicotine than traditional cigarettes, with studies backing their effectiveness. The company is ready to license this technology to other manufacturers, aiming to reduce cigarette addiction and save lives.

22nd Century Group, Inc. (XXII) supports New Zealand's proposal to reduce nicotine in cigarettes to minimal levels, aiming for a smoke-free nation by 2025. The company, known for its reduced nicotine content (RNC) cigarettes, is prepared to aid in this initiative, believing it aligns with public health goals. The firm expects significant global interest in nicotine reduction as New Zealand leads the way, with a focus on aiding smokers to quit. With FDA authorization of their PMTA for RNC cigarettes, 22nd Century is ready to supply the New Zealand market, enhancing its potential for growth in tobacco harm reduction.

22nd Century Group announced that its VP of Regulatory Science, John Pritchard, will join the FDLI Tobacco and Nicotine Products Committee. This committee focuses on tobacco product regulation and aims to advance public health policy by discussing the FDA's proposed nicotine cap for cigarettes. The FDA's plan seeks to lower nicotine to 0.5 mg per gram, deemed minimally addictive. 22nd Century is confident in the final stages of its Modified Risk Tobacco Product application for its VLN® cigarettes, which contain 95% less nicotine than traditional cigarettes, potentially aiding millions in quitting smoking.

22nd Century Group, a leader in plant-based biotechnology, announced its confidence in the FDA's reduced nicotine mandate, supported by four former FDA commissioners. Their VLN® King and VLN® Menthol King products contain 95% less nicotine than traditional cigarettes, making them compliant with the FDA's proposed nicotine cap. A Modified Risk Tobacco Product (MRTP) designation for VLN® is anticipated, potentially allowing the company to promote its low nicotine levels. The company believes this could significantly impact public health by helping over five million people quit smoking in the first year alone.

22nd Century Group (XXII) congratulates Xavier Becerra on his appointment as Secretary of HHS, believing it could revitalize the FDA's plan to regulate nicotine levels in cigarettes. Becerra’s advocacy for a nicotine cap aligns with 22nd Century's mission to reduce harm from smoking. The company highlights that its VLN® product, engineered to contain 95% less nicotine, complies with proposed regulations. The FDA is anticipated to grant a Modified Risk Tobacco Product designation for VLN®, enabling the company to market it effectively to help smokers reduce nicotine exposure.